Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia

NCT03079505 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Protocol Deviation

Conditions

Chronic Myeloid Leukemia - Chronic Phase

Interventions

DRUG: Dasatinib 100 MG [Sprycel]
DRUG: Nilotinib 150mg oral capsule [Tasigna]

Sponsor

Hamad Medical Corporation